SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Serono, Inc. Announces Results From Pivotal Phase III Clinical Trial Of Its Proprietary Recombinant Human Growth Hormone In The Treatment Of HARS At The XVI International AIDS Conference; Trial Achieves Goal